Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endoxifen in Bipolar I Disorder Patients
2024-511829-57-00Phase 3Completed
- Sponsor
- Intas Pharmaceuticals
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in bipolar I disorder comparing Endoxifen with Placebo (2 arms). Primary endpoint: Mean change from baseline to Day 21 on the YMRS Total Score. Started Oct 2024; status: completed.
02
Drugs
z-endoxifen
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2024-511829-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511829-57-00.